Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asciminib in Chronic Phase CML Patients With T315I Mutations
NCT07789574Phase 2Active, not recruiting
- Start
- Jun 2026
- Primary completion
- Jun 2030
- Countries
- 1
01
Overview
A Phase 2 trial of asciminib in chronic myeloid leukemia (CML). Started Jun 2026; status: active, not recruiting.
02
Drugs
asciminib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT07789574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07789574.